Presentation is loading. Please wait.

Presentation is loading. Please wait.

CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment 

Published byBjörn Åberg Modified over 5 years ago

Similar presentations

Presentation on theme: "CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment "— Presentation transcript:

1 CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment  Giulio Metro, MD, Gianluigi Lunardi, PharmD, Piero Floridi, MD, Jennifer P. Pascali, PhD, Luca Marcomigni, MD, Rita Chiari, MD, Vienna Ludovini, PhD, Lucio Crinò, MD, Stefania Gori, MD  Journal of Thoracic Oncology  Volume 10, Issue 5, Pages e26-e27 (May 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Brain MRI (axial T1 postgadolinium) taken from case 1. Brain imaging before crizotinib initiation (A, B, C) shows a small left frontal brain metastasis (A), and a right (B) and left (C) meningeal lesion. A repeat MRI after 4 weeks of crizotinib shows disappearance of all lesions (D, E, F). MRI, magnetic resonance imaging. Journal of Thoracic Oncology  , e26-e27DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment "

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.
Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma  Stefania Gori, MD, Alessandro Inno, MD, PhD, Gianluigi Lunardi,

18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma  Stefania Gori, MD, Alessandro Inno, MD, PhD, Gianluigi Lunardi,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell.

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell.
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
Prevalence of Brain Metastases Immediately before Prophylactic Cranial Irradiation in Limited Disease Small Cell Lung Cancer Patients with Complete Remission.

Prevalence of Brain Metastases Immediately before Prophylactic Cranial Irradiation in Limited Disease Small Cell Lung Cancer Patients with Complete Remission.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib  Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

Similar presentations

Ads by Google